CVE:NRTH

48North Cannabis Competitors

C$0.14
0.00 (0.00 %)
(As of 04/22/2021 03:59 PM ET)
Add
Compare
Today's Range
C$0.14
Now: C$0.14
C$0.16
50-Day Range
C$0.14
MA: C$0.20
C$0.29
52-Week Range
C$0.13
Now: C$0.14
C$0.42
Volume1.88 million shs
Average Volume958,315 shs
Market CapitalizationC$31.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

48North Cannabis (CVE:NRTH) Vs. LABS, KHRN, DN, META, CSI, and BAMM

Should you be buying NRTH stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to 48North Cannabis, including MediPharm Labs (LABS), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), Meta Growth (META), (CSI) (CSI), and 28896 (BAMM).

MediPharm Labs (TSE:LABS) and 48North Cannabis (CVE:NRTH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for MediPharm Labs and 48North Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs02023.00
48North Cannabis0000N/A

MediPharm Labs currently has a consensus target price of C$1.53, indicating a potential upside of 229.03%. Given MediPharm Labs' higher probable upside, equities analysts plainly believe MediPharm Labs is more favorable than 48North Cannabis.

Earnings and Valuation

This table compares MediPharm Labs and 48North Cannabis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$36.01 million3.33C$-123,815,040.00C($0.48)-0.97
48North CannabisC$17.36 million1.82C$-59,218,395.00C($0.26)-0.53

48North Cannabis has lower revenue, but higher earnings than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MediPharm Labs and 48North Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm LabsN/AN/AN/A
48North CannabisN/AN/AN/A

Summary

MediPharm Labs beats 48North Cannabis on 4 of the 7 factors compared between the two stocks.

Khiron Life Sciences (CVE:KHRN) and 48North Cannabis (CVE:NRTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Valuation & Earnings

This table compares Khiron Life Sciences and 48North Cannabis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesC$8.01 million9.09C$-39,493,921.00C($0.26)-1.84
48North CannabisC$17.36 million1.82C$-59,218,395.00C($0.26)-0.53

Khiron Life Sciences has higher earnings, but lower revenue than 48North Cannabis. Khiron Life Sciences is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Khiron Life Sciences and 48North Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences0000N/A
48North Cannabis0000N/A

Khiron Life Sciences currently has a consensus target price of C$1.20, indicating a potential upside of 147.42%. Given Khiron Life Sciences' higher probable upside, analysts clearly believe Khiron Life Sciences is more favorable than 48North Cannabis.

Profitability

This table compares Khiron Life Sciences and 48North Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
48North CannabisN/AN/AN/A

Summary

Khiron Life Sciences beats 48North Cannabis on 3 of the 5 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and 48North Cannabis (CVE:NRTH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Profitability

This table compares Delta 9 Cannabis and 48North Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Delta 9 CannabisN/AN/AN/A
48North CannabisN/AN/AN/A

Valuation and Earnings

This table compares Delta 9 Cannabis and 48North Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$52.05 million1.12C$-7,346,808.00C($0.07)-7.92
48North CannabisC$17.36 million1.82C$-59,218,395.00C($0.26)-0.53

Delta 9 Cannabis has higher revenue and earnings than 48North Cannabis. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Delta 9 Cannabis and 48North Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Delta 9 Cannabis00014.00
48North Cannabis0000N/A

Delta 9 Cannabis presently has a consensus price target of C$1.10, suggesting a potential upside of 92.98%. Given Delta 9 Cannabis' higher possible upside, equities research analysts clearly believe Delta 9 Cannabis is more favorable than 48North Cannabis.

Summary

Delta 9 Cannabis beats 48North Cannabis on 5 of the 7 factors compared between the two stocks.

Meta Growth (CVE:META) and 48North Cannabis (CVE:NRTH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Meta Growth and 48North Cannabis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66
48North CannabisC$17.36 million1.82C$-59,218,395.00C($0.26)-0.53

Meta Growth has higher revenue and earnings than 48North Cannabis. Meta Growth is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Meta Growth and 48North Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meta GrowthN/AN/AN/A
48North CannabisN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Meta Growth and 48North Cannabis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meta Growth0000N/A
48North Cannabis0000N/A

Summary

Meta Growth beats 48North Cannabis on 3 of the 5 factors compared between the two stocks.

48North Cannabis (CVE:NRTH) and (CSI) (CNSX:CSI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Earnings & Valuation

This table compares 48North Cannabis and (CSI)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
48North CannabisC$17.36 million1.82$-59,218,395.00C($0.26)-0.53
(CSI)N/AN/AN/AN/AN/A

(CSI) has lower revenue, but higher earnings than 48North Cannabis.

Analyst Ratings

This is a breakdown of current ratings and target prices for 48North Cannabis and (CSI), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
48North Cannabis0000N/A
(CSI)0000N/A

Profitability

This table compares 48North Cannabis and (CSI)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
48North CannabisN/AN/AN/A
(CSI)N/AN/AN/A

Summary

48North Cannabis beats (CSI) on 1 of the 1 factors compared between the two stocks.

28896 (CNSX:BAMM) and 48North Cannabis (CVE:NRTH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for 28896 and 48North Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
288960000N/A
48North Cannabis0000N/A

Profitability

This table compares 28896 and 48North Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
28896N/AN/AN/A
48North CannabisN/AN/AN/A

Earnings & Valuation

This table compares 28896 and 48North Cannabis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
28896N/AN/AN/AN/AN/A
48North CannabisC$17.36 million1.82C$-59,218,395.00C($0.26)-0.53

28896 has higher earnings, but lower revenue than 48North Cannabis.

Summary

48North Cannabis beats 28896 on 1 of the 1 factors compared between the two stocks.


48North Cannabis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LABS
MediPharm Labs
1.4$0.47flatC$119.95 millionC$36.01 million-0.97
KHRN
Khiron Life Sciences
0.9$0.49flatC$67.34 millionC$8.01 million-1.84
DN
Delta 9 Cannabis
1.4$0.57flatC$58.16 millionC$52.05 million-7.92
META
Meta Growth
0.8$0.14flatC$36.69 millionC$60.96 million-0.66Gap Up
CSI
(CSI)
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATT
Abattis Bioceuticals
0.5N/AN/AC$0.00N/A0.00Gap Down
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
IMCC
IM Cannabis
0.0N/AN/A$0.00N/A0.00High Trading Volume
PULL
Mind Cure Health
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
BUZZ
VanEck Vectors Social Sentiment ETF
1.0N/AN/A$0.00N/A0.00High Trading Volume
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.